Estrogens, progestins, selective estrogen receptor modulators, and the arterial tree

American Journal of Obstetrics and Gynecology

Volumn 184, Issue 5, 2001, Pages 1031-1039

  Wild, Robert A ^a,b   Reis, Steven E ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Artery; Estrogens; Progestins; Selective estrogen receptor modulators; SERMs

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ACTIVATED PROTEIN C; ANTIOXIDANT; ARGININE; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; CONJUGATED ESTROGEN; D DIMER; DROLOXIFENE; ESTRADIOL; ESTROGEN DERIVATIVE; FIBRINOGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ACUTE PANCREATITIS; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL TRIAL; CORONARY RISK; DRUG SELECTIVITY; ESTROGEN THERAPY; HEART PROTECTION; HUMAN; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; VASCULAR ENDOTHELIUM; VASOSPASM; VEIN THROMBOSIS;

EID: 0035059419     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.112902     Document Type: Article

References (128)

1. Biostatistical Fact Sheet
2. Oestrogens and the heart
3. Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon
4. Surrogate end points in clinical trials: Are we being misled?
5. Long-term estrogen therapy abolishes acute estrogen-induced coronary flow augmentation in postmenopausal women
6. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease
7. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects
8. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms
9. Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice
10. Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake
11. Potential cellular signaling mechanisms mediating upregulation of endothelial nitric oxide production by estrogen
12. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice
13. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders
14. Effect of 17β-estradiol in hypercholesterolemic rabbits with severe endothelial dysfunction
15. The protective effect of 17β-estradiol on vasomotor responses of aorta from cholesterolfed rabbit is reduced by inhibitors of superoxide dismutase and catalase
16. Effects of estrogen on atherosclerosis formation and serum nitrite/nitrate concentrations in cholesterol-fed ovariectomized rabbits
17. Antiatherogenic effect of estrogen abolished by balloon catheter injury in cholesterol-clamped rabbits
18. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits
19. Estrogen effects on insulin-like growth factor-I (IGF-I)-induced cell proliferation and IGF-I expression in native and allograft vessels
20. Inhibition of transplant coronary arteriosclerosis in rabbits by chronic estradiol treatment is associated with abolition of MHC class II antigen expression
21. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits
22. 17β-Estradiol induces protein thiol/disulfide oxidoreductases and protects cultured bovine aortic endothelial cells from oxidative stress
23. Estrogens modulate bovine vascular endothelial cell permeability and HSP 25 expression concomitantly
24. Endothelin receptors are modulated in association with endogenous fluctuations in estrogen
25. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor
26. Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries
27. 17βEstradiol acutely [correction of activity] improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
28. Influence of gender on vasomotor effects of oxidized low-density lipoprotein in porcine coronary arteries
29. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP
30. Estrogen restores endothelial cell function in an experimental model of vascular injury
31. Interleukin-1 beta-induced nitric oxide production in rat aortic endothelial cells: Inhibition by estradiol in normal and high glucose cultures
32. Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta
33. 17β-Oestradiol enhances nitric oxide synthase activity in endothelium-denuded rat aorta
34. 17β-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS
35. 17β-Estradiol acts separately on the LDL particle and artery wall to reduce LDL accumulation
36. In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones
37. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys
38. Ca2+ release mechanism of primate drug-induced coronary vasospasm
39. Differential response in cell proliferation to beta estradiol in coronary arterial vascular smooth muscle cells obtained from mature female versus male animals
40. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta
41. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
42. Estrogen replacement inhibits intimal hyperplasia and the accumulation and effects of transforming growth factor beta 1
43. Roles of NO and Ca2+-activated K+ channels in coronary vasodilation induced by 17β-estradiol in ischemic heart failure
44. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
45. Postmenopausal hormone replacement therapy and cardiovascular disease
46. Combined oestrogen-progestin replacement therapy prevents atherosclerosis in postmenopausal women
47. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
48. Endothelial dysfunction in coronary heart disease
49. Coronary risk factors, endothelial function, and atherosclerosis: A review
50. Endothelial dysfunction: Does it matter? Is it reversible?
51. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions
52. Atherosclerosis or lipoprotein-induced endothelial dysfunction: Potential mechanisms underlying reduction in EDRF/nitric oxide activity
53. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury
54. Impaired epicardial coronary vasoreactivity predicts adverse cardiovascular events during long term follow-up
55. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
56. Endothelial cell function: New considerations
57. Regulatory functions of the vascular endothelium
58. Acute vascular effects of estrogen in postmenopausal women
59. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women
60. Oestrogens attenuate abnormal coronary, vasoreactivity in postmenopausal women
61. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women
62. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
63. Localized expression of aromatase in human vascular tissues
64. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists
65. Mechanisms of 17β-oestradiol induced vasodilatation in isolated pressurized rat small arteries
66. Rapid non-genomic vasodilator actions of oestrogens and sex steroids
67. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
68. Design of the Women's Health Initiative clinical trial and observational study
69. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: Results from the estrogen in women with atherosclerosis study
70. Inherited prothrombotic conditions and premature ischemic stroke: Sex difference in the association with factor V Leiden
71. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C)
72. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
73. Effect of estrogen on aortic function in postmenopausal women
74. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal
75. Randomized comparison of oral and transdermal hormone replacement on carotid and uterine artery resistance to blood flow
76. Menopausal status and distensibility of the common carotid artery
77. Alteration in the pulsatility index values of the internal carotid and middle cerebral arteries after suspension of postmenopausal hormone replacement therapy: A randomized crossover study
78. Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes
79. Age-related deterioration in arterial structure and function in postmenopausal women: Impact of hormone replacement therapy
80. Hormone replacement therapy and intima-media thickness of the common carotid artery: The Rotterdam study
81. Carotid artery wall changes in estrogen-treated and -untreated postmenopausal women
82. Hormone replacement therapy in postmenopausal women: Carotid intima-media thickness and 3-D volumetric plaque quantification
83. Carotid atherosclerosis in premenopausal and postmenopausal women and its association with risk factors measured after menopause
84. Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular structure and function
85. Coronary and aortic calcification among women 8 years after menopause and their premenopausal risk factors: The healthy women study
86. No association of menopause and hormone replacement therapy with carotid artery intima-media thickness
87. Norethindrone acetate enhances the antiatherogenic effect of 17β-estradiol: A secondary prevention study of aortic atherosclerosis in ovariectomized cholesterol-fed rabbits
88. Effects of progestogens on haemostasis
89. Cardiovascular disease and steroid hormone contraception
90. The HERS trial results: Paradigms lost? Heart and Estrogen/Progestin Replacement Study
91. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: Lack of an effect of added progesterone
92. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm
93. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys
94. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery
95. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women
96. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function
97. Effects of CP-336,156, a next, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models
98. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model
99. Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator
100. Droloxifene (3-hydroxytamoxifen) has membrane antioxidant ability: Potential relevance to its mechanism of therapeutic action in breast cancer
101. Andoxidant properties of the triphenylethylene antiestrogen drug toremifene
102. Inhibition of LDL oxidation and myeloperoxidase dependent trosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)
103. Inhibition of LDL oxidation by a new estradiol receptor modulator compound LY-139478, comparative effect with other steroids
104. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism
105. Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran
106. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice
107. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys
108. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
109. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
110. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
111. The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
112. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer
113. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
114. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women
115. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized controlled trial
116. Tamoxifen reduces plasma homocysteine levels in healthy women
117. A randomized controlled study of the effects of 17β-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women
118. Tamoxifen for early breast cancer: An overview of the randomised trials
119. Coronary heart disease mortality and adjuvant tamoxifen therapy
120. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxephene
121. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
122. Effects of estrogen and raloxifen, a selective estrogen receptor modulator, in animal models of vascular injury
123. Estradiol effect on rate of proliferation of rat carotid segments: Effect of gender and tamoxifen
124. The effect of tamoxifen and transdermal 17β-estradiol on cerebral arterial vessels: A randomized controlled study
125. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: Results of an international, multicenter, case-control study
126. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications
127. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting
128. Postmenopausal hormone therapy and mortality